{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:30:04Z","timestamp":1767209404023,"version":"build-2238731810"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,28]]},"DOI":"10.7759\/cureus.78138","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T12:38:09Z","timestamp":1738067889000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of Dual Antiplatelet Therapy Versus Monotherapy in Acute Stroke Management: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Adil Areeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiren B","family":"Hisoriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javeria","family":"Mithani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwatobiloba T","family":"Ogungbemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kesha","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rauda","family":"Al Dhaheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Zubair","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishath","family":"Kausar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3238165","article-title":"Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life","volume":"2018","author":"Donkor ES","year":"2018","unstructured":"Donkor ES. Stroke in the 21st century: a snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat. 2018, 2018:3238165. 10.1155\/2018\/3238165","journal-title":"Stroke Res Treat"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.06.039","article-title":"Antithrombotic therapy to prevent recurrent strokes in ischemic cerebrovascular disease: JACC Scientific Expert Panel","volume":"74","author":"Del Brutto VJ","year":"2019","unstructured":"Del Brutto VJ, Chaturvedi S, Diener HC, Romano JG, Sacco RL. Antithrombotic therapy to prevent recurrent strokes in ischemic cerebrovascular disease: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019, 74:786-803. 10.1016\/j.jacc.2019.06.039","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.053782","article-title":"Efficacy and safety of using dual versus monotherapy antiplatelet agents in secondary stroke prevention: systematic review and meta-analysis of randomized controlled clinical trials","volume":"143","author":"Trifan G","year":"2021","unstructured":"Trifan G, Gorelick PB, Testai FD.  Efficacy and safety of using dual versus monotherapy antiplatelet agents in secondary stroke prevention: systematic review and meta-analysis of randomized controlled clinical trials. Circulation. 2021, 143:2441-53. 10.1161\/CIRCULATIONAHA.121.053782","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3310\/MNJY9014","article-title":"Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies","volume":"27","author":"Harris J","year":"2023","unstructured":"Harris J, Pouwels KB, Johnson T, et al.. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies. Health Technol Assess. 2023, 27:1-257. 10.3310\/MNJY9014","journal-title":"Health Technol Assess"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.10.002","article-title":"Association between genetic polymorphisms and sites of cervicocerebral artery atherosclerosis","volume":"21","author":"Chutinet A","year":"2012","unstructured":"Chutinet A, Suwanwela NC, Snabboon T, Chaisinanunkul N, Furie KL, Phanthumchinda K. Association between genetic polymorphisms and sites of cervicocerebral artery atherosclerosis. J Stroke Cerebrovasc Dis. 2012, 21:379-85. 10.1016\/j.jstrokecerebrovasdis.2010.10.002","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.07.005","article-title":"Using the full PICO model as a search tool for systematic reviews resulted in lower recall for some PICO elements","volume":"127","author":"Frandsen TF","year":"2020","unstructured":"Frandsen TF, Bruun Nielsen MF, Lindhardt CL, Eriksen MB. Using the full PICO model as a search tool for systematic reviews resulted in lower recall for some PICO elements. J Clin Epidemiol. 2020, 127:69-75. 10.1016\/j.jclinepi.2020.07.005","journal-title":"J Clin Epidemiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2015.02.002","article-title":"Eligibility criteria in systematic reviews: a methodological review","volume":"52","author":"McCrae N","year":"2015","unstructured":"McCrae N, Blackstock M, Purssell E. Eligibility criteria in systematic reviews: a methodological review. Int J Nurs Stud. 2015, 52:1269-76. 10.1016\/j.ijnurstu.2015.02.002","journal-title":"Int J Nurs Stud"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.122.040507","article-title":"Association between CYP2B6 polymorphisms and efficacy of clopidogrel in minor stroke or transient ischemic attack","volume":"54","author":"Qiu X","year":"2023","unstructured":"Qiu X, Zhang Y, Gu H, et al.. Association between CYP2B6 polymorphisms and efficacy of clopidogrel in minor stroke or transient ischemic attack. Stroke. 2023, 54:1770-6. 10.1161\/STROKEAHA.122.040507","journal-title":"Stroke"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107988","article-title":"Time to treatment and disability attributed to index stroke in the POINT trial","volume":"33","author":"Balali P","year":"2024","unstructured":"Balali P, Easton JD, Johnston SC, Cucchiara B. Time to treatment and disability attributed to index stroke in the POINT trial. J Stroke Cerebrovasc Dis. 2024, 33:107988. 10.1016\/j.jstrokecerebrovasdis.2024.107988","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022575","article-title":"Dual antiplatelet therapy using cilostazol in patients with stroke and intracranial arterial stenosis","volume":"10","author":"Uchiyama S","year":"2021","unstructured":"Uchiyama S, Toyoda K, Omae K, et al.. Dual antiplatelet therapy using cilostazol in patients with stroke and intracranial arterial stenosis. J Am Heart Assoc. 2021, 10:e022575. 10.1161\/JAHA.121.022575","journal-title":"J Am Heart Assoc"},{"key":"ref12","article-title":"Dual antiplatelet use for extended period targeted to acute ischemic stroke with presumed atherosclerotic origin (DURATION) trial: rationale and design","volume":"18","author":"Kim JT","year":"2023","unstructured":"Kim JT, Kang J, Kim BJ, et al.. Dual antiplatelet use for extended period targeted to acute ischemic stroke with presumed atherosclerotic origin (DURATION) trial: rationale and design. Int J Stroke. 2023, 18:1015-20.","journal-title":"Int J Stroke"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200064","article-title":"Association of timing for starting dual antiplatelet treatment with cilostazol and recurrent stroke: a CSPS.com trial post hoc analysis","volume":"98","author":"Toyoda K","year":"2022","unstructured":"Toyoda K, Omae K, Hoshino H, et al.. Association of timing for starting dual antiplatelet treatment with cilostazol and recurrent stroke: a CSPS.com trial post hoc analysis. Neurology. 2022, 98:e983-92. 10.1212\/WNL.0000000000200064","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105115","article-title":"Ipsilateral nonstenotic carotid disease in minor ischemic stroke: an exploratory analysis of the POINT randomized clinical trial","volume":"29","author":"Bulwa Z","year":"2020","unstructured":"Bulwa Z, Saleh Velez FG, Brorson JR, Pinto CB. Ipsilateral nonstenotic carotid disease in minor ischemic stroke: an exploratory analysis of the POINT randomized clinical trial. J Stroke Cerebrovasc Dis. 2020, 29:105115. 10.1016\/j.jstrokecerebrovasdis.2020.105115","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.637686","article-title":"Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Geeganage CM","year":"2012","unstructured":"Geeganage CM, Diener HC, Algra A, et al.. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke. 2012, 43:1058-66. 10.1161\/STROKEAHA.111.637686","journal-title":"Stroke"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd11020048","article-title":"Dual antiplatelet therapy for the acute management and long-term secondary prevention of ischemic stroke and transient ischemic attack, an updated review","volume":"11","author":"Chan BP","year":"2024","unstructured":"Chan BP, Wong LY, Tan BY, Yeo LL, Venketasubramanian N. Dual antiplatelet therapy for the acute management and long-term secondary prevention of ischemic stroke and transient ischemic attack, an updated review. J Cardiovasc Dev Dis. 2024, 11:48. 10.3390\/jcdd11020048","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.895342","article-title":"Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial","volume":"121","author":"Berger PB","year":"2010","unstructured":"Berger PB, Bhatt DL, Fuster V, et al.. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010, 121:2575-83. 10.1161\/CIRCULATIONAHA.109.895342","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.6705\/j.jacme.202209_12(3).0001","article-title":"Dual antiplatelet therapy in the management of acute minor ischemic stroke and high-risk transient ischemic attack: an expert consensus statement from Taiwan Stroke Society and Taiwan Society of Emergency Medicine","volume":"12","author":"Chen PL","year":"2022","unstructured":"Chen PL, Chen YJ, Chung CP, et al.. Dual antiplatelet therapy in the management of acute minor ischemic stroke and high-risk transient ischemic attack: an expert consensus statement from Taiwan Stroke Society and Taiwan Society of Emergency Medicine. J Acute Med. 2022, 12:85-95. 10.6705\/j.jacme.202209_12(3).0001","journal-title":"J Acute Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.12703\/r\/11-19","article-title":"Recent advances in the management of transient ischemic attacks","volume":"11","author":"Ortiz-Garcia J","year":"2022","unstructured":"Ortiz-Garcia J, Gomez CR, Schneck MJ, Biller J. Recent advances in the management of transient ischemic attacks. Fac Rev. 2022, 11:19. 10.12703\/r\/11-19","journal-title":"Fac Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.755167","article-title":"Transient ischemic attacks preceding ischemic stroke and the possible preconditioning of the human brain: a systematic review and meta-analysis","volume":"12","author":"Ghozy S","year":"2021","unstructured":"Ghozy S, Kacimi SE, Elfil M, et al.. Transient ischemic attacks preceding ischemic stroke and the possible preconditioning of the human brain: a systematic review and meta-analysis. Front Neurol. 2021, 12:755167. 10.3389\/fneur.2021.755167","journal-title":"Front Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-023-01892-9","article-title":"Personalized dual antiplatelet therapy in acute coronary syndromes: striking a balance between bleeding and thrombosis","volume":"25","author":"Shpigelman J","year":"2023","unstructured":"Shpigelman J, Proshkina A, Daly MJ, Cox D. Personalized dual antiplatelet therapy in acute coronary syndromes: striking a balance between bleeding and thrombosis. Curr Cardiol Rep. 2023, 25:693-710. 10.1007\/s11886-023-01892-9","journal-title":"Curr Cardiol Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309137","article-title":"Dual antiplatelet treatment up to 72 hours after ischemic stroke","volume":"389","author":"Gao Y","year":"2023","unstructured":"Gao Y, Chen W, Pan Y, et al.. Dual antiplatelet treatment up to 72 hours after ischemic stroke. N Engl J Med. 2023, 389:2413-24. 10.1056\/NEJMoa2309137","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.512","article-title":"Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Bittl JA","year":"2016","unstructured":"Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016, 68:1116-39. 10.1016\/j.jacc.2016.03.512","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1405","article-title":"Genetic polymorphisms in pharmaceuticals and chemotherapy","volume":"12","author":"Gummadi AC","year":"2021","unstructured":"Gummadi AC, Guddati AK. Genetic polymorphisms in pharmaceuticals and chemotherapy. World J Oncol. 2021, 12:149-54. 10.14740\/wjon1405","journal-title":"World J Oncol"}],"updated-by":[{"DOI":"10.7759\/cureus.r176","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"record-id":"63936"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/333113-impact-of-dual-antiplatelet-therapy-versus-monotherapy-in-acute-stroke-management-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T12:38:12Z","timestamp":1738067892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/333113-impact-of-dual-antiplatelet-therapy-versus-monotherapy-in-acute-stroke-management-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.78138","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,28]]}}}